Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Ambrx Biopharma Inc. AMAM NYSE

NYSE • Healthcare • Biotechnology • US • USD

SharesGrow Score
28/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Ambrx Biopharma Inc. (AMAM) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 2 Buy, 4 Hold.

AMAM Analyst Ratings

Hold
6
Ratings
2 Buy
4 Hold
Based on 6 analysts giving stock ratings to Ambrx Biopharma Inc. in the past 3 months
Rating breakdown
Buy
2 33%
Hold
4 67%
33%
Buy
2 analysts
67%
Hold
4 analysts
0%
Sell
0 analysts

People Also View

DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.47
+0.05%
 VECT
VECT
VectivBio Holding AG
$16.87
+0.12%
 IMMX
IMMX
Immix Biopharma, Inc.
$10.04
+1.93%
 ZURA
ZURA
Zura Bio Limited
$5.69
-0.52%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 ABOS
ABOS
Acumen Pharmaceuticals, Inc.
$2.72
+1.49%
 XFOR
XFOR
X4 Pharmaceuticals, Inc.
$4.33
+3.10%
 ELEV
ELEV
Elevation Oncology, Inc.
$0.37
-2.12%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message